Economical evaluation of darunavir plus low dose ritonavir intreatment-experienced HIV-1-infected patients

被引：0
|
作者：
Vorobiev, P. [1 ]
Avksentieva, M. [1 ]
Lesnicheva, M. [2 ]
机构：
[1] Moscow Med Acad, Moscow, Russia
[2] Russian Soc Pharmacoecon & Outcomes Res, Moscow, Russia
来源：
VALUE IN HEALTH | 2008年 / 11卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)70317-X
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A98 / A98
页数：1
相关论文
共 50 条
  • [31] Population pharmacokinetics of lopinavir/ritonavir (LPVr) in HIV-1-infected patients
    Crommentuyn, KML
    Kappelhoff, BS
    Mulder, JW
    Mairuhu, ATA
    van Gorp, ECM
    Meenhorst, PL
    Huitema, ADR
    Beijnen, JH
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 59 (05) : 609 - 610
  • [32] Pharmacokinetics and pharmacodynamics of the nucleoside sparing dual regimen containing rilpivirine plus darunavir/ritonavir in treatment-naive HIV-1-infected individuals
    Jackson, Akil
    Else, Laura
    Higgs, Christopher
    Karolia, Zeenat
    Khoo, Saye
    Back, David
    Devitt, Emma
    Pozniak, Anton
    Boffito, Marta
    HIV CLINICAL TRIALS, 2018, 19 (01): : 31 - 37
  • [33] Pharmacokinetics of darunavir/ritonavir during pregnancy in HIV-1-infected women (vol 17, pg 643, 2016)
    Crauwels, H. M.
    Kakuda, T. N.
    Ryan, B.
    Zorilla, C.
    HIV MEDICINE, 2019, 20 (07) : 496 - 499
  • [34] Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis
    Mills, Anthony M.
    Nelson, Mark
    Jayaweera, Dushyantha
    Ruxrungtham, Kiat
    Cassetti, Isabel
    Girard, Pierre-Marie
    Workman, Cassy
    Dierynck, Inge
    Sekar, Vanitha
    Abeele, Carline Vanden
    Lavreys, Ludo
    AIDS, 2009, 23 (13) : 1679 - 1688
  • [35] Cost Effectiveness of Darunavir/Ritonavir 600/100 mg bid in Protease Inhibitor-Experienced, HIV-1-Infected Adults in Belgium, Italy, Sweden and the UK
    Moeremans, Karen
    Annemans, Lieven
    Lothgren, Mickael
    Allegri, Gabriele
    Wyffels, Veronique
    Hemmet, Lindsay
    Caekelbergh, Karin
    Smets, Erik
    PHARMACOECONOMICS, 2010, 28 : 107 - 128
  • [36] Cost of switching darunavir plus ritonavir (DRV plus RTV) to lopinavir/ritonavir (LPV/r) in HIV-1-infected treatment-na ve women of child-bearing age (WOCBA)
    Baran, R.
    Moller, J.
    Desai, K.
    Simpson, K.
    Van de Steen, O.
    Dietz, B.
    Gooch, K.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2012, 15 : 67 - 67
  • [37] Evaluation of super-boosted lopinavir/ritonavir in combination with rifampicin in HIV-1-infected patients with tuberculosis
    Boulanger, Catherine
    Rolla, Valeria
    Al-Shaer, Mohammad H.
    Peloquin, Charles
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2020, 55 (02)
  • [38] Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients
    Kappelhoff, BS
    Huitema, ADR
    Sankatsing, SUC
    Meenhorst, PL
    Van Gorp, ECM
    Mulder, JW
    Prins, JM
    Beijnen, JH
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 60 (03) : 276 - 286
  • [39] Model Based Dosing Rationale for Darunavir when Co-administered with Low-dose Ritonavir in Pediatric HIV-1 Infected Patients
    Brochot, Anne
    Vis, Peter
    Van De Casteele, Tom
    Opsomer, Magda
    Tomaka, Frank
    Vermeulen, An
    Kakuda, Thomas N.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2013, 40 : S89 - S90
  • [40] Plasma and saliva concentrations of abacavir, tenofovir, darunavir, and raltegravir in HIV-1-infected patients
    Yamada, Eiko
    Takagi, Ritsuo
    Tanabe, Yoshinari
    Fujiwara, Hiroshi
    Hasegawa, Naoki
    Kato, Shingo
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2017, 55 (07) : 567 - 570
12345